See more : Gujarat Poly Electronics Limited (GUJARATPOLY.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hainan Huluwa Pharmaceutical Group Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Wonlim Corporation (005820.KS) Income Statement Analysis – Financial Results
- Funko, Inc. (FNKO) Income Statement Analysis – Financial Results
- Pacific Assets Trust plc (PAC.L) Income Statement Analysis – Financial Results
- Air France-KLM SA (AFLYY) Income Statement Analysis – Financial Results
- Intercontinental International Real Estate Investment Company (INTERCO.AT) Income Statement Analysis – Financial Results
Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
About Hainan Huluwa Pharmaceutical Group Co., Ltd.
Hainan Huluwa Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of drugs in the areas of Children's respiratory and digestive systems in China. Its primary products include 4 grams of pediatric lung heat cough granules and capsules. The company was founded in 2005 and is based in Haikou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.91B | 1.52B | 1.35B | 1.16B | 1.31B | 983.77M | 655.01M | 487.35M |
| Cost of Revenue | 907.79M | 638.58M | 545.10M | 443.65M | 496.79M | 379.95M | 336.98M | 291.21M |
| Gross Profit | 997.39M | 876.46M | 808.70M | 718.05M | 809.13M | 603.82M | 318.03M | 196.15M |
| Gross Profit Ratio | 52.35% | 57.85% | 59.74% | 61.81% | 61.96% | 61.38% | 48.55% | 40.25% |
| Research & Development | 93.92M | 105.66M | 100.43M | 51.66M | 51.66M | 43.33M | 19.62M | 11.20M |
| General & Administrative | 25.80M | 15.29M | 23.24M | 25.95M | 24.45M | 14.68M | 12.00M | 36.37M |
| Selling & Marketing | 504.38M | 584.27M | 545.58M | 475.30M | 549.65M | 388.03M | 145.96M | 91.01M |
| SG&A | 756.43M | 599.56M | 568.82M | 501.24M | 574.10M | 402.71M | 157.96M | 127.38M |
| Other Expenses | 10.11M | 47.78M | 53.88M | 11.21M | 24.99M | 1.90M | 1.22M | 5.68M |
| Operating Expenses | 868.41M | 753.00M | 723.13M | 564.11M | 650.75M | 477.70M | 269.01M | 144.19M |
| Cost & Expenses | 1.77B | 1.39B | 1.27B | 1.01B | 1.15B | 857.65M | 605.98M | 435.40M |
| Interest Income | 1.34M | 2.01M | 3.77M | 880.41K | 225.41K | 402.92K | 922.17K | 867.17K |
| Interest Expense | 18.55M | 18.00M | 13.87M | 9.10M | 13.36M | 8.91M | 14.49M | 11.38M |
| Depreciation & Amortization | 59.72M | 51.57M | 48.40M | 43.82M | 41.95M | 35.79M | 28.95M | 28.42M |
| EBITDA | 213.41M | 167.67M | 148.17M | 189.46M | 198.51M | 163.24M | 78.89M | 82.86M |
| EBITDA Ratio | 11.20% | 11.49% | 10.97% | 17.05% | 15.54% | 16.91% | 12.27% | 17.86% |
| Operating Income | 136.94M | 96.62M | 100.30M | 134.17M | 141.55M | 116.58M | 34.16M | 37.38M |
| Operating Income Ratio | 7.19% | 6.38% | 7.41% | 11.55% | 10.84% | 11.85% | 5.22% | 7.67% |
| Total Other Income/Expenses | -1.44M | 605.10K | -18.64M | 216.37K | 690.57K | 1.90M | 1.22M | 5.68M |
| Income Before Tax | 135.49M | 97.23M | 81.66M | 134.39M | 142.24M | 118.48M | 35.38M | 43.06M |
| Income Before Tax Ratio | 7.11% | 6.42% | 6.03% | 11.57% | 10.89% | 12.04% | 5.40% | 8.84% |
| Income Tax Expense | 22.87M | 12.49M | 12.11M | 12.89M | 21.91M | 17.94M | 13.25M | 9.30M |
| Net Income | 106.50M | 85.68M | 72.14M | 121.50M | 120.33M | 100.54M | 22.13M | 33.76M |
| Net Income Ratio | 5.59% | 5.66% | 5.33% | 10.46% | 9.21% | 10.22% | 3.38% | 6.93% |
| EPS | 0.27 | 0.21 | 0.18 | 0.30 | 0.30 | 0.31 | 0.13 | 0.56 |
| EPS Diluted | 0.27 | 0.21 | 0.18 | 0.30 | 0.30 | 0.31 | 0.13 | 0.56 |
| Weighted Avg Shares Out | 394.44M | 400.11M | 400.11M | 400.11M | 400.11M | 324.32M | 170.21M | 400.11M |
| Weighted Avg Shares Out (Dil) | 394.44M | 400.11M | 400.11M | 400.11M | 400.11M | 324.32M | 170.21M | 400.11M |
Source: https://incomestatements.info
Category: Stock Reports